Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 3.5%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell 3.5% during trading on Tuesday . The stock traded as low as $1,051.00 and last traded at $1,053.87. 88,696 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 470,871 shares. The stock had previously closed at $1,091.98.

Analyst Ratings Changes

A number of brokerages have recently commented on REGN. Barclays upped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Royal Bank of Canada reissued an “outperform” rating and issued a $1,282.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 17th. Argus boosted their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,120.05.

Regeneron Pharmaceuticals Stock Down 4.1 %

The firm has a market cap of $115.41 billion, a price-to-earnings ratio of 30.82, a PEG ratio of 3.93 and a beta of 0.12. The business’s 50-day moving average is $1,131.94 and its 200-day moving average is $1,033.46. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the business posted $8.79 earnings per share. The company’s revenue was up 12.3% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The disclosure for this sale can be found here. Insiders sold 9,270 shares of company stock valued at $10,695,833 in the last three months. Corporate insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in REGN. Greater Midwest Financial Group LLC raised its holdings in Regeneron Pharmaceuticals by 8.8% during the 2nd quarter. Greater Midwest Financial Group LLC now owns 2,502 shares of the biopharmaceutical company’s stock worth $2,894,000 after purchasing an additional 203 shares during the last quarter. Centaurus Financial Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $118,000. Prio Wealth Limited Partnership bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $210,000. Sanctuary Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $47,611,000. Finally, Kestra Investment Management LLC bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $437,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.